What is it about?

Cases continue to accumulate associating SGLT2 inhibitors with acute pancreatitis, a potentially dangerous condition. This paper presents a case of of acute pancreatitis likely caused by use of dapagliflozin. It also reviews other cases associated with all other drugs in this class.

Featured Image

Why is it important?

Acute pancreatitis is not listed as a warning when using dapagliflozin or other SGLT2 inhibitors. Patients and prescribers need to be aware of this potential risk.

Read the Original

This page is a summary of: Probable Dapagliflozin-Associated Acute Pancreatitis, Diabetes Spectrum, September 2021, American Diabetes Association,
DOI: 10.2337/ds21-0025.
You can read the full text:

Read

Contributors

The following have contributed to this page